Kymera Therapeutics, Inc. KYMR 深 滬
等待開盤 03-26 09:30:00 美东时间
78.93
+4.510
+6.06%
華盛通- 最 高81.31
- 今 開76.00
- 成交量 93.50万股
- 最 低 75.71
- 昨 收 74.42
- 總市值 64.44亿
- 52周最高 103.00
- 市盈率 靜 --
- 換手率 1.15%
- 52周最低 19.445
- 委 比 2.74%
- 總股本 8164.24万
- 歷史最高 103.00
- 量 比 1.38
- 振 幅 7.52%
- 歷史最低 9.60
- 每 手 1
- 風險率 19.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monda
03-16 18:00
Kymera Therapeutics To Present Eczema Drug Trial Results At Major Dermatology Conference
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that data from its KT-621
03-10 19:04
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Kymera Therapeutics announced that data from its KT-621 Phase 1b clinical trial for atopic dermatitis will be presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting in Denver, CO. The presentation, titled "Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results," will take place on March 28, 2026, at 9:24 AM MT in the Bellco Theatre. KT-621 is a first-in-c...
03-10 11:00
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Piper Sandler Maintains Overweight on Kymera Therapeutics, Raises Price Target to $140
Piper Sandler analyst Biren Amin maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $125 to $140.
02-27 00:37
Kymera Therapeutics Establishes New $500 Million ATM Program
Kymera Therapeutics ( ($KYMR) ) has issued an announcement. On February 26, 202...
02-26 21:51
财报速睇 | Kymera Therapeutics, Inc. 2025财年Q4营收0.03亿美元，同比下降61.2%；归母净利润亏损0.87亿美元，同比亏损扩大22.9%
华盛资讯2月26日讯，Kymera Therapeutics, Inc.公布2025财年Q4业绩，公司Q4营收0.03亿美元，同比下降61.2%，归母净利润亏损0.87亿美元，同比亏损扩大22.9%。
02-26 20:40
